Sentence: Neoadjuvant trastuzumab , pertuzumab , and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer ( KRISTINE ): a randomised , open-label , multicentre , phase 3 trial .
Drug combination annotation:
[{'class': 'POS', 'spans': ['trastuzumab', 'pertuzumab', 'trastuzumab emtansine', 'pertuzumab'], 'is_context_needed': True}]